Pre-clinical research results show that WARF Therapeutics' WT-7695 radiopharmaceutical, which uses SHINE's Ilumira, achieved 100% survival in a model of kidney cancer
ART-101, a novel prostate cancer treatment developed at the Advanced Radiotheranostics Lab using SHINE's Ilumira, demonstrates superior efficacy compared to current therapies
JANESVILLE, Wis., Oct. 17, 2024 /PRNewswire/ -- SHINE Technologies, a next-generation fusion company, and WARF Therapeutics, a drug discovery program by the Wisconsin Alumni Research Foundation (WARF), today announced promising pre-clinical research results from collaborative efforts with Advanced Radiotheranostics Lab at the University of Wisconsin-Madison. The studies showed that WT-7695 and ART-101 – treatments that leverage SHINE's non-carrier added lutetium-177 (Lu-177) chloride, Ilumira – have the potential to increase life span and be more effective in treating kidney and prostate cancer, respectively.
Partnering with both UW-Madison and Morgridge Institute for Research Principal Investigators, WARF Therapeutics creates a translational research path that taps world-renowned research and an industry-focused approach to improve value propositions of drug candidates.
